What Is Biphalin? Definition and What Research Reports
Biphalin is a synthetic dimeric (bivalent) opioid peptide made of two enkephalin-like tetrapeptide sequences joined tail-to-tail through a hydrazide bridge. It is a laboratory compound, not a natural product and not an approved medicine, and it appears in the literature mainly as a research tool for studying multireceptor opioid pharmacology. Published work is preclinical: reports describe antinociceptive activity in rodent pain models, effects in models of brain injury and excitotoxicity, gastrointestinal transit effects, and in vitro corneal epithelial wound-healing changes.
Definition
Biphalin is a synthetic dimeric opioid peptide — an octapeptide built by joining two enkephalin-like tetrapeptide fragments tail-to-tail through a hydrazide linker, so that a single molecule carries two opioid pharmacophores. It is not extracted from tissue, not a hormone, and not an approved medicine anywhere; it is a laboratory-made analogue of the endogenous enkephalins that was designed to interact with more than one opioid receptor subtype at once. In the published literature the name "biphalin" is used almost exclusively as a chemical identifier for this specific bivalent structure and for the large family of analogues derived from it. A 2016 review characterised biphalin as the structural foundation for subsequent bivalent opioid ligand design (PMID 27160537), and a medicinal-chemistry review of biphalin analogues surveyed how changes to the two arms and the bridge altered activity at opioid receptors (PMID 22512573).
What Class of Molecule It Is
Biphalin belongs to the opioid peptide class. Endogenous opioid peptides such as the enkephalins are short sequences that act at mu (MOP), delta (DOP) and kappa (KOP) opioid receptors; biphalin is a fully synthetic relative of that family rather than a naturally occurring sequence. Because two pharmacophores sit on one backbone, it is also described in the literature as a bivalent or dimeric ligand, and reviews have used it as the reference example when discussing how bivalency changes opioid receptor engagement (PMID 27160537). Studies have referred to it as a mixed MOP/DOP agonist (PMID 26721348) and, elsewhere, as a multireceptor opioid peptide (PMID 21842273).
Where It Comes From
Biphalin is produced by chemical peptide synthesis. A 2020 methods chapter used biphalin as a worked case study for solution-phase peptide synthesis, describing the assembly of the dimeric sequence in solution rather than on solid support (PMID 31879915). Chemists have also modified the finished molecule: researchers reported that conjugating low-molecular-weight poly(ethylene glycol) to biphalin altered and enhanced its antinociceptive profile in their experiments (PMID 12820142).
How the Term Is Used in Peptide Research
In peptide science, "biphalin" usually appears in one of three contexts:
- As a pharmacological tool. Papers use it to probe what happens when mu and delta opioid receptors are engaged simultaneously, and to compare that profile against single-receptor reference agonists such as morphine (PMID 27094782).
- As a chemical scaffold. Structure–activity relationship work has generated large numbers of biphalin analogues, with reviews cataloguing how substitutions changed opioid receptor activity (PMID 22512573).
- As a design concept. The molecule is cited as the starting point for the broader bivalent-ligand strategy in opioid chemistry (PMID 27160537).
It is not a term used for a marketed drug, a dietary ingredient, or a clinical protocol. Materials described as biphalin in catalogues are research chemicals, and this page is descriptive only.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Published Literature Reports
The verified literature on biphalin is preclinical — rodent models, cell and tissue culture, and chemistry reviews. The summaries below describe what the cited papers reported in those settings; they are not statements about effects in people.
Pain models
A 2016 study in a mouse model of cancer pain reported that biphalin preferentially recruited peripheral opioid receptors to produce analgesia and compared that behaviour with morphine (PMID 27094782). Earlier chemistry work reported that PEG conjugation enhanced the antinociceptive profile of the parent peptide (PMID 12820142). A 2021 review in International Journal of Molecular Sciences discussed biphalin as a potent opioid agonist and surveyed its investigation across opioid-system-dependent pathophysiological conditions (PMID 34768778).
Brain injury and excitotoxicity models
Researchers reported in a 2021 mouse study that biphalin reduced neonatal hypoxia–ischaemia brain injury and linked the effect to activation of PI3K/Akt signalling (PMID 33992725). A 2016 study reported that biphalin protected against cognitive deficits in a mouse model of mild traumatic brain injury (PMID 26474659). In organotypic hippocampal culture, the study examined biphalin as a multireceptor opioid peptide against excitotoxic injury and reported neuroprotective potential in that system (PMID 21842273). A 2021 pharmacology paper examined glutamate buffering capacity and blood–brain barrier protection for the opioid receptor agonists biphalin and nociceptin (PMID 34663677).
Gastrointestinal and ocular models
A 2016 report described biphalin, as a mixed MOP/DOP agonist, eliciting an anti-transit effect in mouse models mimicking diarrhoea-predominant irritable bowel syndrome symptoms (PMID 26721348). Separately, a 2021 in vitro study reported that the opioid peptide biphalin modulated human corneal epithelial wound healing in culture (PMID 34446298).
Research contexts at a glance
| Research context | Model system described | Citation |
|---|---|---|
| Cancer pain / analgesia | Mouse model, compared with morphine | PMID 27094782 |
| Neonatal hypoxia–ischaemia | Mouse; PI3K/Akt pathway | PMID 33992725 |
| Mild traumatic brain injury | Mouse cognitive testing | PMID 26474659 |
| Excitotoxic injury | Hippocampal organotypic culture | PMID 21842273 |
| Blood–brain barrier / glutamate | Comparison with nociceptin | PMID 34663677 |
| Gastrointestinal transit | Mouse IBS-D-like models | PMID 26721348 |
| Corneal epithelium | Human cells in vitro | PMID 34446298 |
| Chemistry and analogues | Synthesis and SAR reviews | PMID 31879915, PMID 22512573 |
Safety and Tolerability: What Studies Report
The verified literature indexed here does not include human clinical safety trials of biphalin, and no adverse-event rates in people are reported in these papers. The 2021 review framed biphalin within opioid-system pharmacology and examined its agonist profile in that context (PMID 34768778), while the structure–activity review discussed how analogue modifications changed receptor activity rather than reporting clinical outcomes (PMID 22512573). Because biphalin is an opioid receptor agonist, its pharmacology sits in a drug class with well-documented regulatory controls; nothing in the cited preclinical work speaks to safety, dosing or tolerability outside the animal and cell systems those papers described.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appRelated Terms
- Enkephalin — the endogenous opioid pentapeptide family whose sequence motif forms each arm of biphalin (PMID 27160537).
- Bivalent ligand — a molecule carrying two pharmacophores; biphalin is cited as a foundational example (PMID 27160537).
- MOP/DOP agonist — terminology used for mixed mu/delta opioid receptor activity (PMID 26721348).
- Solution-phase peptide synthesis — the manufacturing route illustrated using biphalin as the case study (PMID 31879915).
This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or any decision involving a drug, peptide or supplement. Biphalin is a research compound, and the findings summarised here come from preclinical studies.
References
- Biphalin—A Potent Opioid Agonist—As a Panacea for Opioid System-Dependent Pathophysiological Diseases? (International Journal of Molecular Sciences, 2021)
- Structure-activity relationships of biphalin analogs and their biological evaluation on opioid receptors (Mini Reviews in Medicinal Chemistry, 2013)
- Biphalin: The Foundation of Bivalent Ligands (Current Medicinal Chemistry, 2016)
- Solution Phase Peptide Synthesis: The Case of Biphalin (Methods in Molecular Biology, 2020)
- Conjugation of low molecular weight poly(ethylene glycol) to biphalin enhances antinociceptive profile (Journal of Pharmaceutical Sciences, 2003)
- Biphalin preferentially recruits peripheral opioid receptors to facilitate analgesia in a mouse model of cancer pain - A comparison with morphine (European Journal of Pharmaceutical Sciences, 2016)
- Biphalin, a dimeric opioid peptide, reduces neonatal hypoxia-ischemia brain injury in mice by the activation of PI3K/Akt signaling pathway (Journal of Chemical Neuroanatomy, 2021)
- Biphalin protects against cognitive deficits in a mouse model of mild traumatic brain injury (mTBI) (Neuropharmacology, 2016)
- Glutamate Buffering Capacity and Blood-Brain Barrier Protection of Opioid Receptor Agonists Biphalin and Nociceptin (Journal of Pharmacology and Experimental Therapeutics, 2021)
- Neuroprotective potential of biphalin, multireceptor opioid peptide, against excitotoxic injury in hippocampal organotypic culture (Neurochemical Research, 2011)
- Mixed MOP/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms (Pharmacological Reports, 2016)
- The opioid peptide biphalin modulates human corneal epithelial wound healing in vitro (Journal Français d'Ophtalmologie, 2021)
Frequently asked questions
What is biphalin in one sentence?▾
Biphalin is a synthetic dimeric opioid peptide in which two enkephalin-like tetrapeptide fragments are joined tail-to-tail through a hydrazide bridge, giving one molecule two opioid pharmacophores. Reviews describe it as the foundational example of bivalent opioid ligand design (PMID 27160537) and as a scaffold whose analogues have been catalogued in structure–activity studies at opioid receptors (PMID 22512573).
Is biphalin a natural peptide?▾
No. It is made by chemical synthesis rather than isolated from tissue, although each of its two arms resembles the endogenous enkephalin sequence. A 2020 methods chapter used biphalin specifically as a worked example of solution-phase peptide synthesis (PMID 31879915), and chemists have further modified the finished peptide, for instance by conjugating low-molecular-weight PEG to it (PMID 12820142).
Which receptors does the literature associate with biphalin?▾
Published work describes biphalin as engaging more than one opioid receptor subtype. One 2016 gastrointestinal study referred to it as a mixed MOP/DOP agonist (PMID 26721348), and an earlier culture study called it a multireceptor opioid peptide (PMID 21842273). A 2021 review discussed it as a potent opioid agonist across opioid-system-dependent conditions (PMID 34768778).
What have animal studies reported about biphalin?▾
Researchers reported analgesia through preferential recruitment of peripheral opioid receptors in a mouse cancer pain model compared with morphine (PMID 27094782), reduced neonatal hypoxia–ischaemia brain injury in mice via PI3K/Akt signalling (PMID 33992725), and protection against cognitive deficits in a mouse mild traumatic brain injury model (PMID 26474659). All of these were preclinical animal experiments.
Has biphalin been studied outside pain research?▾
Yes, in several non-pain preclinical contexts. A 2021 in vitro study reported that biphalin modulated human corneal epithelial wound healing in culture (PMID 34446298). Another 2021 paper examined glutamate buffering capacity and blood–brain barrier protection for biphalin and nociceptin (PMID 34663677), and a mouse study described an anti-transit effect in IBS-D-like models (PMID 26721348).
Is biphalin an approved medicine?▾
The verified literature describes biphalin as a research compound studied in animals, tissue culture and chemistry laboratories, not as an approved therapeutic product. Reviews have framed it within opioid pharmacology and analogue design rather than clinical practice (PMID 34768778, PMID 22512573). This information is educational only and is not medical advice; medical questions belong with a licensed physician.
Why is biphalin called a bivalent ligand?▾
Because a single biphalin molecule carries two copies of an opioid pharmacophore rather than one, a design intended to let it interact with opioid receptors differently from single-pharmacophore peptides. A 2016 review presented biphalin as the foundation of the bivalent ligand approach (PMID 27160537), and analogue reviews have examined how altering the arms or bridge changed receptor activity (PMID 22512573).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.